BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-64. [PMID: 23629668 DOI: 10.3390/ijms14059338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
2 Soares AB, Altemani A, de Oliveira TR, de Oliveira Fonseca Rodrigues F, Ribeiro-Silva A, Soave DF, Passador-Santos F, Brum ST, Napimoga MH, de Araújo VC. Comparison of the blood and lymphatic microvessel density of pleomorphic adenoma and Basal cell adenoma. Clin Med Insights Pathol 2015;8:17-21. [PMID: 25987856 DOI: 10.4137/CPath.S23035] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Shi Y, Su C, Hu H, Yan H, Li W, Chen G, Xu D, Du X, Zhang P. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. PLoS One 2018;13:e0198896. [PMID: 29949618 DOI: 10.1371/journal.pone.0198896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Nasir A. Angiogenic Signaling Pathways and Anti-angiogenic Therapies in Human Cancer. In: Badve S, Kumar GL, editors. Predictive Biomarkers in Oncology. Cham: Springer International Publishing; 2019. pp. 243-62. [DOI: 10.1007/978-3-319-95228-4_19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R, Tan EH. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett 2017;388:328-33. [PMID: 28003122 DOI: 10.1016/j.canlet.2016.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Yang WH, Xu J, Mu JB, Xie J. Revision of the concept of anti-angiogenesis and its applications in tumor treatment. Chronic Dis Transl Med 2017;3:33-40. [PMID: 29063054 DOI: 10.1016/j.cdtm.2017.01.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
7 Chen S, Le T, Harley BAC, Imoukhuede PI. Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification. Front Bioeng Biotechnol 2018;6:92. [PMID: 30050899 DOI: 10.3389/fbioe.2018.00092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
8 Li D, Finley SD. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment. Integr Biol (Camb) 2018;10:253-69. [PMID: 29623971 DOI: 10.1039/c8ib00019k] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
9 Yang Q, Wang X, Cui J, Wang P, Xiong M, Jia C, Liu L, Ning B, Li L, Wang W, Chen Y, Zhang T. Bidirectional regulation of angiogenesis and miR-18a expression by PNS in the mouse model of tumor complicated by myocardial ischemia. BMC Complement Altern Med 2014;14:183. [PMID: 24903055 DOI: 10.1186/1472-6882-14-183] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
10 Tu M, Lu C, Lv N, Wei J, Lu Z, Xi C, Chen J, Guo F, Jiang K, Li Q, Wu J, Song G, Wang S, Gao W, Miao Y. Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2. Cancer Letters 2016;383:272-81. [DOI: 10.1016/j.canlet.2016.09.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
11 Multhoff G, Radons J, Vaupel P. Critical role of aberrant angiogenesis in the development of tumor hypoxia and associated radioresistance. Cancers (Basel) 2014;6:813-28. [PMID: 24717239 DOI: 10.3390/cancers6020813] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
12 Momeny M, Sankanian G, Hamzehlou S, Yousefi H, Esmaeili F, Alishahi Z, Karimi B, Zandi Z, Shamsaiegahkani S, Sabourinejad Z, Kashani B, Nasrollahzadeh A, Mousavipak SH, Mousavi SA, Ghaffari SH. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells. Eur J Pharmacol 2020;882:173298. [PMID: 32593665 DOI: 10.1016/j.ejphar.2020.173298] [Reference Citation Analysis]
13 Aversa C, Leone F, Zucchini G, Serini G, Geuna E, Milani A, Valdembri D, Martinello R, Montemurro F. Linifanib: current status and future potential in cancer therapy. Expert Review of Anticancer Therapy 2015;15:677-87. [DOI: 10.1586/14737140.2015.1042369] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
14 Najjar F, Alammar M, Bachour M, Al-Massarani G. Circulating endothelial cells as a biomarker in non-small cell lung cancer patients: correlation with clinical outcome. Int J Biol Markers 2014;29:e337-44. [PMID: 25041783 DOI: 10.5301/jbm.5000100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
15 Powell D, Chandra S, Dodson K, Shaheen F, Wiltz K, Ireland S, Syed M, Dash S, Wiese T, Mandal T, Kundu A. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm 2017;114:108-18. [PMID: 28131717 DOI: 10.1016/j.ejpb.2017.01.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
16 Zhang M, Liu J, Liu G, Xing Z, Jia Z, Li J, Wang W, Wang J, Qin L, Wang X, Wang X. Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies. Cancer Lett 2021;520:422-33. [PMID: 34389434 DOI: 10.1016/j.canlet.2021.08.005] [Reference Citation Analysis]
17 Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. Int J Mol Sci 2017;18:E461. [PMID: 28230776 DOI: 10.3390/ijms18020461] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
18 Vilsmaier T, Rack B, Janni W, Jeschke U, Weissenbacher T; SUCCESS Study Group. Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment. BMC Cancer 2016;16:547. [PMID: 27464822 DOI: 10.1186/s12885-016-2612-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
19 Bendtsen MAF, Grimm D, Bauer J, Wehland M, Wise P, Magnusson NE, Infanger M, Krüger M. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. Int J Mol Sci 2017;18:E1736. [PMID: 28796163 DOI: 10.3390/ijms18081736] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
20 Clancy A, Spaans J, Weberpals J. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy. Annals of Oncology 2016;27:1696-705. [DOI: 10.1093/annonc/mdw242] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
21 Fagiani E, Bill R, Pisarsky L, Ivanek R, Rüegg C, Christofori G. An immature B cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models. Angiogenesis 2015;18:327-45. [PMID: 26021306 DOI: 10.1007/s10456-015-9470-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Tegnebratt T, Lu L, Eksborg S, Chireh A, Damberg P, Nikkhou-Aski S, Foukakis T, Rundqvist H, Holmin S, Kuiper RV, Samen E. Treatment response assessment with (R)-[11CPAQ PET in the MMTV-PyMT mouse model of breast cancer. EJNMMI Res 2018;8:25. [PMID: 29616369 DOI: 10.1186/s13550-018-0380-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. J Clin Oncol. 2016;34:2728-2735. [PMID: 27325864 DOI: 10.1200/jco.2015.65.1901] [Cited by in Crossref: 110] [Cited by in F6Publishing: 67] [Article Influence: 22.0] [Reference Citation Analysis]
24 Gacche RN, Meshram RJ. Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2014;1846:161-79. [DOI: 10.1016/j.bbcan.2014.05.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 68] [Article Influence: 6.1] [Reference Citation Analysis]
25 Finley SD, Dhar M, Popel AS. Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol 2013;3:196. [PMID: 23908970 DOI: 10.3389/fonc.2013.00196] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
26 Fruscella M, Ponzetto A, Crema A, Carloni G. The Extraordinary Progress in Very Early Cancer Diagnosis and Personalized Therapy: The Role of Oncomarkers and Nanotechnology. Journal of Nanotechnology 2016;2016:1-18. [DOI: 10.1155/2016/3020361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
27 Wu Q, Arnheim AD, Finley SD. In silico mouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment. J R Soc Interface 2018;15:20180243. [PMID: 30135261 DOI: 10.1098/rsif.2018.0243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Zhang T, Yu T, Zhang D, Hou X, Liu X, Zhao D, Shan L. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0963-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
29 Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, Tovari J, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B. Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics 2017;7:400-12. [PMID: 28042343 DOI: 10.7150/thno.16767] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
30 Ye W. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. Developmental Cell 2016;37:114-25. [DOI: 10.1016/j.devcel.2016.03.015] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 15.2] [Reference Citation Analysis]
31 Budolfsen C, Faber J, Grimm D, Krüger M, Bauer J, Wehland M, Infanger M, Magnusson NE. Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. CVP 2019;17:618-34. [DOI: 10.2174/1570161117666190130165810] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
32 Zhao Y, Adjei AA. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 2015;20:660-73. [PMID: 26001391 DOI: 10.1634/theoncologist.2014-0465] [Cited by in Crossref: 266] [Cited by in F6Publishing: 254] [Article Influence: 44.3] [Reference Citation Analysis]
33 Ancker OV, Wehland M, Bauer J, Infanger M, Grimm D. The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors. Int J Mol Sci 2017;18:E625. [PMID: 28335429 DOI: 10.3390/ijms18030625] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
34 Gaddy TD, Wu Q, Arnheim AD, Finley SD. Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment. PLoS Comput Biol 2017;13:e1005874. [PMID: 29267273 DOI: 10.1371/journal.pcbi.1005874] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
35 Lotti R, Palazzo E, Petrachi T, Dallaglio K, Saltari A, Truzzi F, Quadri M, Puviani M, Maiorana A, Marconi A, Pincelli C. Survivin Modulates Squamous Cell Carcinoma-Derived Stem-Like Cell Proliferation, Viability and Tumor Formation in Vivo. Int J Mol Sci 2016;17:E89. [PMID: 26771605 DOI: 10.3390/ijms17010089] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
36 Kristensen TB, Knutsson ML, Wehland M, Laursen BE, Grimm D, Warnke E, Magnusson NE. Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci 2014;15:23024-41. [PMID: 25514409 DOI: 10.3390/ijms151223024] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
37 Dost Gunay FS, Kırmızı BA, Ensari A, İcli F, Akbulut H. Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer. Clin Colorectal Cancer 2019;18:e244-50. [PMID: 30670344 DOI: 10.1016/j.clcc.2018.12.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Zhao S, Gong Z, Zhang J, Xu X, Liu P, Guan W, Jing L, Peng T, Teng J, Jia Y. Elevated Serum MicroRNA Let-7c in Moyamoya Disease. J Stroke Cerebrovasc Dis 2015;24:1709-14. [PMID: 26070522 DOI: 10.1016/j.jstrokecerebrovasdis.2015.01.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
39 Nakagawa S, Okabe H, Ouchi M, Tokunaga R, Umezaki N, Higashi T, Kaida T, Arima K, Kitano Y, Kuroki H, Mima K, Nitta H, Imai K, Hashimoto D, Yamashita Y, Chikamoto A, Baba H. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma. HPB 2018;20:939-48. [DOI: 10.1016/j.hpb.2018.03.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
40 Gupta P, Arumugam M, Azad RV, Saxena R, Ghose S, Biswas NR, Velpandian T. Screening of antiangiogenic potential of twenty two marine invertebrate extracts of phylum Mollusca from South East Coast of India. Asian Pac J Trop Biomed 2014;4:S129-38. [PMID: 25183067 DOI: 10.12980/APJTB.4.2014C701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
41 Meng XY, Zhang Q, Li Q, Lin S, Li J. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations. J Int Med Res 2014;42:619-27. [PMID: 24670538 DOI: 10.1177/0300060513505485] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]